title: [Can human recombinant erythropoietin (rHuEPO) be considered as cardiological medicine?].
abstract: Recombinant human erythropoietin (rHuEPO) is a hormone essential for normal erythropoiesis. The rHuEPO receptor is distributed in the cardiovascular system predominantly in endothelial cells and cardiomyocytes. RHuEPO has potentially beneficial effects on cardiovascular system, including anti-apoptic, mitogenic and angiogenic activity. On the other hand rHuEPO improves anemia observed in some patients with heart failure. Direct cardiac activity of rHuEPO and indirect influence on anemia suggest that rHuEPO therapy is safe and useful in chronic heart failure patients and other cardiovascular settings.
authors.affiliation: Katedra Medycyny Rodzinnej, Zakład Podstawowej Opieki Zdrowotnej Akademii Medycznej w Lublinie.
authors.forename: Piotr
authors.initials: P
authors.lastname: Ksiazek
authors.forename: Andrzej
authors.initials: A
authors.lastname: Ksiazek
mesh_terms: D002309:Cardiology / Q000379:methods*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002908:Chronic Disease; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin